Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Updates Surg ; 74(1): 203-211, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34142314

ABSTRACT

INTRODUCTION: We sought to evaluate the effect of age on postoperative outcomes among patients undergoing major liver surgery for perihilar cholangiocarcinoma (PHCC). METHODS: 77 patients were included. Patients were categorized into two groups: the "< 70-year-olds" group (n = 54) and the "≥ 70-year-olds" group (n = 23). RESULTS: Median LOS was 19 both for < 70-year-old group and ≥ 70-year-old group (P = 0.72). No differences in terms of severe complication were detected (44.4% Clavien-Dindo 3-4-5 in < 70-year-old group vs 47.8% in ≥ 70-year-old group, P = 0.60). Within 90 postoperative days, 11 patients died, 6 in < 70-year-old group (11.3%) and 5 in ≥ 70-year-old group (21.7%), P = 0.29. The median follow-up was 20 months. The death rate was 72.2% and 78.3% among patients < 70 years old and ≥ 70 years old. The OS at 2 and 5 years was significantly higher among the < 70 years old (57.0% and 27.7%) compared to the ≥ 70 years old (27.1% and 13.6%), P = 0.043. Adjusting for hypertension and Charlson comorbidity index in a multivariate analysis, the HR for age was 1.93 (95% CI 0.84-4.44), P = 0.12. Relapse occurred in 43 (81.1%) patients in the < 70-year-old group and in 19 (82.6%) patients in the ≥ 70-year-old group. DFS at 12, 24, and 36 months was, respectively, 59.6, 34.2, and 23.2 for the < 70 -year-old group and 32.5, 20.3, and 13.5 for the ≥ 70-year-old group (P = 0.26). Adjusting for hypertension and Charlson comorbidity index in a Cox model, the HR for age was 1.52 (95% CI 0.67-3.46), with P = 0.32. CONCLUSIONS: ≥ 70-year-old patients with PHCC can still be eligible for major liver resection with acceptable complication rates and should not be precluded a priori from a radical treatment.


Subject(s)
Bile Duct Neoplasms , Cholangiocarcinoma , Klatskin Tumor , Aged , Bile Duct Neoplasms/surgery , Cholangiocarcinoma/surgery , Hepatectomy , Humans , Klatskin Tumor/surgery , Neoplasm Recurrence, Local , Proportional Hazards Models , Retrospective Studies
3.
Asian J Surg ; 43(2): 401-404, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31320233

ABSTRACT

BACKGROUND: Fistula-in-ano is one of the most commonly presenting anorectal diseases. Sphincter sparing treatment options should be considered in patients with complex fistulas. Salvecoll-E gel is a native collagen deantigenated and purified, non-cross-linked equine dermal extract, with an amino acid composition identical to human collagen. METHODS: The multicentric trial study was a prospective, single-arm observational clinical study with the objective to assess the efficacy of Salvecoll-E gel for anal fistula repair in 70 patients. All patients had undergone preliminary surgical treatment consisting of positioning of a draining loosing seton that was maintained for a period of 4-6 weeks. After seton removal, a gentle debridement and washing of the fistula track was performed. The scar tissue was removed from the internal orifice. Internal opening was covered by a side-to side mucosal suture. Salvecoll-E was injected through the external opening into the fistula track, the external opening it has been opened. RESULTS: Twelve months after surgery, 55 patients demonstrated a clinically healed fistula (78,5%), 15 patients have a recurrence (21,5%). Most of the recurrences were observed in the first 6 months of treatment (13/15, 86.6%). We don't observe any worsening in CCF score. The results obtained at 1 year certainly seem satisfactory and in line with the best results published in literature using mini-invasive techniques. CONCLUSION: Salvecoll-E gel is a promising non-invasive technique for conservative treatment of anal fistulas, it's well tolerated by the patients and, in case of recurrence, reinjection or all other known techniques are feasible.


Subject(s)
Anal Canal , Anus Diseases/surgery , Collagen/administration & dosage , Collagen/therapeutic use , Fistula/surgery , Organ Sparing Treatments/methods , Rectal Diseases/surgery , Animals , Horses , Prospective Studies , Recurrence , Treatment Outcome
4.
Clin Ter ; 143(3): 213-7, 1993 Sep.
Article in Italian | MEDLINE | ID: mdl-8222552

ABSTRACT

The above study was undertaken in order to demonstrate the efficacy of ketanserin in mild to moderate essential arterial hypertension. Twenty-two patients, mean age 49.7 yrs., were studied during 36 months. After a 15-day washout period with clinical and instrumental assessment of basal conditions, treatment with 40 mg ketanserin every 12 hrs. was started. Pressure, blood chemistry and instrumental investigation were carried out systematically and showed the hypotensive action of ketanserin as well as a significant (about 12%) rise in HDL-cholesterol.


Subject(s)
Hypertension/drug therapy , Ketanserin/therapeutic use , Adult , Blood Pressure/drug effects , Cholesterol, HDL/blood , Cholesterol, HDL/drug effects , Drug Evaluation , Female , Humans , Ketanserin/administration & dosage , Male , Middle Aged
5.
Eur Neurol ; 31(6): 345-7, 1991.
Article in English | MEDLINE | ID: mdl-1756756

ABSTRACT

Two siblings presented the typical skin changes of hypomelanosis of Ito (HI) associated with mental and cerebellar signs. Their mother showed only the skin changes of HI but no neurological disturbances. HI is a hereditary disorder, in which familiarity may go unnoticed because of the different expressions of neural and cutaneous features.


Subject(s)
Nervous System Diseases/genetics , Pigmentation Disorders/genetics , Adult , Atrophy , Biopsy , Cerebellar Ataxia/diagnosis , Cerebellar Ataxia/genetics , Cerebellar Ataxia/pathology , Cerebellum/pathology , Chromosome Aberrations/genetics , Chromosome Disorders , Genes, Dominant/genetics , Humans , Male , Melanins/metabolism , Melanocytes/pathology , Nervous System Diseases/diagnosis , Nervous System Diseases/pathology , Neurocognitive Disorders/diagnosis , Neurocognitive Disorders/genetics , Neurocognitive Disorders/pathology , Neurologic Examination , Pigmentation Disorders/diagnosis , Pigmentation Disorders/pathology , Skin/pathology
6.
Eur Neurol ; 29(5): 298-300, 1989.
Article in English | MEDLINE | ID: mdl-2792153

ABSTRACT

Since the age of 2, a 16-year-old mentally retarded epileptic girl has had sudden bursts of rapid blinking associated with upward eye deviation and triggered by active or passive head movements. Video EEG monitoring excluded an epileptic origin. Of several hypotheses (brainstem or basal ganglia dysfunction, vestibular origin, and tics), none fully explains this peculiar movement disorder, the origin of which remains unclear.


Subject(s)
Blinking , Head/physiology , Intellectual Disability/physiopathology , Movement Disorders/etiology , Adolescent , Epilepsy/etiology , Female , Humans , Intellectual Disability/complications , Movement Disorders/physiopathology
8.
Int J Clin Pharmacol Res ; 7(6): 499-502, 1987.
Article in English | MEDLINE | ID: mdl-3440640

ABSTRACT

Twenty-nine patients, hospitalized in order to undergo gynaecological surgery involving organ removal, were treated with a single intramuscular administration of 1 g ceftriaxone before surgery. The tissue levels of the drug determined in the organs considered: uterus, ovary, fallopian tubes, vagina, proved to be comparable and to guarantee its satisfactory and uniform penetration into the tissues of the female genital system at a slowly decreasing rate. The high levels observed 12 h and 24 h after administration (2.24 +/- 0.74 mcg/g; 3.58 +/- 0.60 mcg/g; 0.70 +/- 0.45 mcg/g; 1.20 +/- 0.57 mcg/g in the ovaries and myometrium respectively) suggest a possible application of ceftriaxone in presurgical prophylaxis also in cases of female genital surgery.


Subject(s)
Ceftriaxone/pharmacokinetics , Genitalia, Female/metabolism , Adolescent , Adult , Aged , Female , Humans , Hysterectomy , Middle Aged , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...